2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
8
Barrett Esophagus
7
Gastritis
5
Breast Neoplasms
4
Stomach Ulcer
3
Peptic Ulcer
3
Gastroesophageal Reflux
3
Dyspepsia
3
Zollinger-Ellison Syndrome
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Vomiting
1
Radiation Esophagitis
1
Precancerous Conditions
1
Peptic Ulcer Hemorrhage
1
Neoplasms
1
Neoplasm Metastasis
1
Nausea
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Hot Flashes
1
Hemorrhage
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer
1
Esophagitis, Peptic
1
Esophagitis
1
Dysbiosis
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Imatinib Mesylate
71
Sunitinib
31
regorafenib
17
nilotinib
15
ripretinib
13
avapritinib
7
Laparoscopy
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
CTLA-4 Antigen
4
Blood Specimen Collection
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Paclitaxel
3
Oxaliplatin
3
Observation
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Biopsy
3
Bevacizumab
3
trametinib
2
tanespimycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
Esomeprazole
×
Clear all
NCT02800330
2018-08-02
REGORA
Erasmus Medical Center
Phase 4
Completed
31 enrolled